Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 1
Tests an oncolytic adenovirus immunotherapy in adults with recurrent glioblastoma
Tests a virus-based immunotherapy, given repeatedly, in adults with recurrent glioblastoma.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- Amsterdam and Rotterdam, NetherlandsSee the 2 sites
- Trial code
- Registry title
- A Phase I Study using Oncolytic AdenoVirus Immunotherapy with Repeat Administrations in Recurrent GliOblastoma (VIRAGO)
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 18 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 16 Sept 2030
- Type of study
- Interventional
- Record updated
- 21 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose glioblastoma, a type of brain tumour, has come back. It tests an oncolytic adenovirus immunotherapy given more than once.
- Age
- 18 Years and older
- Sex
- All sexes can join
- Disease stage
- Recurrent glioblastoma (the tumour has come back)
Main reasons for not taking part
- Healthy volunteers cannot join
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsNot yet recruiting
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Tests an oncolytic adenovirus immunotherapy in adults with recurrent glioblastomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 21 August 2026